t(14;20)(q32;q12) IGH/MAFB in Plasma Cell Myeloma

Show full item record

Files in this item

PDF 09-2018-t1420q32q12IGHMAFBID1313.pdf 275.4Kb

Pour citer ce document :
URI: http://hdl.handle.net/2042/70482  |   DOI : https://doi.org/10.4267/2042/70482
Title: t(14;20)(q32;q12) IGH/MAFB in Plasma Cell Myeloma
Author: Micale, Mark A
Abstract: Plasma cell myeloma (PCM) is a complex and genetically heterogenous hematological malignancy involving clonal proliferation of plasma cells in bone marrow. It is the third most common hematolymphoid malignancy in the United States and primarily affects elderly people with a median onset age of 69 years and a survival duration ranging from a few months to more than 10 years. Standard karyotype and fluorescence in situ hybridization (FISH) evaluation of bone marrow is required in the initial diagnostic workup to risk stratify patients based on their cytogenetic status. Primary cytogenetic events are classified as either hyperdiploid or non-hyperdiploid. Common in non-hyperdiploid cases is rearrangement of the IGH gene on chromosome 14q32.33, most commonly with the CCND1 gene at 11q13.3, and to a lesser extent FGFR3/MMSET genes at 4p16.3 or the MAF gene at 16q23.2. The rarest of these IGH translocations involves the MAFB gene at 20q12, which is the subject of this review.
Subject: Plasma cell myeloma; Multiple myeloma; MAFB; IGH; APOBEC; Leukaemia Section; Aged; Databases, Genetic; Disease Progression; Female; Gene Expression Profiling; *Gene Expression Regulation, Neoplastic; Genomics; Humans; Male; Middle Aged; Multiple Myeloma/genetics/pathology; Mutation/genetics; Risk Factors; Smoldering Multiple Myeloma/*genetics/pathology; Biomarkers, Tumor/*analysis; Disease Progression; Humans; Monoclonal Gammopathy of Undetermined Significance/*diagnosis/*pathology; Multiple Myeloma/*diagnosis/*pathology; Prognosis; Bone Marrow/*pathology
Publisher: ARMGHM - Atlas Génétique des Cancers
Date: 2019

This item appears in the following Collection(s)

Show full item record

Advanced Search